A reminder , November is Lung Cancer Month and great research is being done to find a cure for one of the most deadliest cancers . 250,000 people just in the USA are losing their battle with Lung Cancer every year , it only has a 17% survival rate . TAKE-HOME MESSAGE •An ASCO expert panel reviewed current molecular testing guidelines for lung cancer and endorsed a set of recommendations that outlines if, when, and how molecular testing should be performed for EGFR mutations, anaplastic lymphoma kinase (ALK) rearrangements, and other genetic alterations in lung cancer patients. The ASCO panel addressed three issues in particular, including new developments in ALK testing, issues to be considered in making decisions about which populations should receive genetic testing, and new possible targets for genetic testing. •The ASCO expert panel endorses the ACP/IASLC/AMP guidelines regarding appropriate use of molecular testing for EGFR mutations, ALK rearrangements, and other genetic alterations. ABSTRACT PURPOSE The College of American Pathologists (CAP), the International Society for the Study of Lung Cancer (IASLC), and the Association of Molecular Pathologists (AMP) guideline on molecular testing for the selection of patients with lung cancer for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors was considered for endorsement. METHODS American Society of Clinical Oncology (ASCO) staff reviewed the CAP/IASLC/AMP guideline for developmental rigor; an ASCO ad hoc review panel of experts reviewed the guideline content. RESULTS The ASCO panel concurred that the recommendations are clear, thorough, and based on the most relevant scientific evidence in this content area and present options that will be acceptable to patients. The CAP/IASLC/AMP guideline comprises 37 recommendations (evidence grade A or B), expert consensus opinions, or suggestions that address the following five principal questions: (1) When should molecular testing be performed? (2) How should EGFR testing be performed?(3) How should ALK testing be performed? (4) Should other genes be routinely tested in lung adenocarcinoma? (5) How should molecular testing be implemented and operationalized? CONCLUSION The ASCO review panel endorses the CAP/IASLC/AMP guideline. This guideline represents an important advance toward standardization of EGFR and ALK testing practices and is of major clinical relevance in advancing the care of patients with lung cancer. In the Discussion section, the ASCO review panel highlights three evolving areas: advances in ALK testing methodology, considerations for selecting appropriate populations for molecular testing, and emergence of other targetable molecular alterations. Journal of Clinical Oncology Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Society for the Study of Lung Cancer/Association of Molecular Pathologists Guideline J. Clin. Oncol 2014 Oct 13;[EPub Ahead of Print], NB Leighl, N Rekhtman, WA Biermann, J Huang, M Mino-Kenudson, SS Ramalingam, H West, S Whitlock, MR Somerfield
Posted on: Wed, 19 Nov 2014 19:53:24 +0000
Trending Topics
Recently Viewed Topics
© 2015